AUPH Jun 2024 5.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.7000

+0.2500

(+55.56%)

At close: 09:49AM EDT

Loading interactive chart...

Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta, May 30, 2024--Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Simply Wall St.
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.